Ascendis Pharma Stock (NASDAQ:ASND)


ForecastChart

Previous Close

$197.67

52W Range

$118.03 - $208.16

50D Avg

$184.96

200D Avg

$158.83

Market Cap

$11.84B

Avg Vol (3M)

$468.67K

Beta

0.39

Div Yield

-

ASND Company Profile


Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

DK

Employees

1,017

IPO Date

Jan 28, 2015

Website

ASND Performance


Latest Earnings Call Transcripts


Q2 22Aug 10, 22 | 10:36 PM
Q1 22May 11, 22 | 11:29 PM
Q4 21Mar 02, 22 | 8:23 PM

Peer Comparison


TickerCompany
BPMCBlueprint Medicines Corporation
ARGXargenx SE
APLSApellis Pharmaceuticals, Inc.
AKROAkero Therapeutics, Inc.
LEGNLegend Biotech Corporation
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks